New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
04:55 EDTCRME, CRME, ALR, ALR, GALE, GALE, BIND, BIND, AVNR, AVNR, OCRX, OCRX, ONVO, ONVO, OSIR, OSIR, SGNT, SGNT, SNTA, SNTA, CRIS, CRISJMP Securities to hold a conference
Healthcare Conference to be held in New York on June 24-25.
News For CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS From The Last 14 Days
Check below for free stories on CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
14:34 EDTALRZwanziger says Alere will not provide due diliegence
Ron Zwanziger disclosed that he sent an email to Gregg Powers, Alere's Chairman of the Board, seeking a meeting to discuss the proposed due diligence period. Zwanziger also noted that representatives from a private equity firm and an investment bank would accompany him to the meeting to discuss equity and debt financing related to the proposed transaction and to assure Mr. Powers that the proposal is and will be bona fide. Zwanziger said Powers responded by letter, declining the proposed meeting. He also indicated that Alere would not be providing any due diligence opportunity to the former officers. Powers also stated in the Alere Letter that the board would appropriately consider any proposal it believes to be bona fide and would maximize shareholder value.
September 17, 2014
16:32 EDTSGNTSagent Pharmaceuticals announces launch of Ketorolac Tromethamine Injection
Subscribe for More Information
September 16, 2014
08:54 EDTALRAlere CEO takeover attempt lacks financing details, says Raymond James
Subscribe for More Information
07:31 EDTALREuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:18 EDTALRAlere worth $45-$50 to strategic buyer, says Canaccord
Canaccord noted the former Chairman and CEO of Alere revealed a proposed buyout of $46 per share. The firm feels the filing indicates genuine interest and believes the company may be worth $45-$50 to a strategic buyer. Canaccord raised its price target to $46 to match the offer and reiterates its Buy rating on the shares.
September 15, 2014
19:32 EDTALRAlere responds to letter from former executives
Subscribe for More Information
17:09 EDTAVNROn The Fly: Closing Wrap
Stocks on Wall Street were mixed to begin the week, as the Dow managed to register mild gains but the Nasdaq was weighed down by slides in a number of so-called "momentum stocks" like Tesla (TSLA). Investors may remain cautious in the next two sessions ahead of the Fed's much anticipated rate decision and accompanying statement, which is due Wednesday. ECONOMIC EVENTS: In the U.S., New York Fed's Empire state survey for September rose to a five-year high of 27.54. Industrial production unexpectedly dipped 0.1% in August from a downwardly revised 0.2% July gain, missing the forecast for a rise of 0.3%. Capacity utilization dropped to 78.8% last month from 79.1% previously. In China, industrial output increased 6.9% in August versus the same period a year earlier, which was its weakest advance, excluding months that fell during New Year holidays, since December 2008. Chinese retail sales growth for August came in at 11.9%, missing the consensus estimate. COMPANY NEWS: Shares of Apple (AAPL) edged down 3c, or 0.03%, to $101.63 despite the company's announcement that a record 4M iPhone 6 and iPhone 6 Plus pre-orders were placed in the first 24 hours that ordering was available. Demand for the new phones exceeds the initial pre-order supply, the company added, stating that delivery of "many" iPhone pre-orders have been pushed out to October... Microsoft (MSFT) slid 45c, or 0.97%, to $46.24 after the company confirmed an agreement to acquire Mojang, the developer for the "Minecraft" video game franchise, for $2.5B... MAJOR MOVERS: Among the notable gainers was Avanir Pharmaceuticals (AVNR), which surged $5.75, or 85.31%, to $12.49 and was upgraded to Buy from Hold at Jefferies after the company announced results from its phase II clinical trial evaluating the safety and efficacy of its treatment of agitation in patients with Alzheimer's disease. Also higher was SABMiller (SBMRY), which jumped $4.72, or 8.5%, to $60.26 after the Wall Street Journal said that ABInBev (BUD) was looking to obtain financing for an acquisition of the U.K.-based brewer and Heineken (HEINY) confirmed that it rebuffed SABMiller's approach regarding a potential transaction. The news of potential consolidation in the space also drove other beer makers highers, with Molson Coors (TAP) rising $4.20, or 5.85%, to $76.00 and Boston Beer (SAM) gaining 71c, or 0.33%, to $218.47. Among the noteworthy losers was Tesla (TSLA), which dropped $25.34, or 9.08%, to $253.86 after Morgan Stanley analyst Adam Jones wrote that he agrees with the assertion of Tesla's CEO Elon Musk that the company's stock may have gotten ahead of itself. Also lower were shares of NPS Pharmaceuticals (NPSP), which fell $5.42, or 16.56%, to $27.28 after Oppennheimer and Jefferies stated that approval of its Natpara drug for hypoparathyroidism could be delayed after concerns were raised during an FDA panel meeting, even though the advisors were in favor of approving the drug. INDEXES: The Dow rose 43.63, or 0.26%, to 17,031.14, the Nasdaq dropped 48.70, or 1.07%, to 4,518.90, and the S&P 500 declined 1.41, or 0.07%, to 1,984.13.
13:11 EDTAVNRAvanir upgraded to Buy from Hold at Jefferies
12:31 EDTALR, AVNROn The Fly: Midday Wrap
Subscribe for More Information
10:36 EDTAVNRHigh option volume stocks
Subscribe for More Information
10:21 EDTAVNRAvanir price target raised to $12.20 on positive Alzheimer data at Cowen
Subscribe for More Information
09:47 EDTAVNRAvanir price target raised to $17 from $13 at Piper Jaffray
09:35 EDTAVNRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA RSH YHOO GILD TWTR AVNR NFLX BAC C
09:15 EDTALRRon Zwanziger plans to offer $46 per share to aquire Alere
Subscribe for More Information
08:32 EDTAVNRAvanir announces positive Phase II results for AVP-923
Subscribe for More Information
06:13 EDTAVNRStocks with implied volatility top IV index mean; AMD AVNR
Subscribe for More Information
September 11, 2014
11:29 EDTAVNROptions with increasing implied volatility
Options with increasing implied volatility: VNET AVNR GPRO RAX FTR JDSU PSEC APD SYY GGP
September 10, 2014
07:05 EDTCRISRodman & Renshaw to hold a conference
Subscribe for More Information
September 9, 2014
07:13 EDTGALEGalena doses first patient in GALE-401 Phase 2 clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use